The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Open accessAbstract
Summary Integrated multi-omics evaluation of 823 tumors from advanced renal cell carcinoma (RCC) patients identifies molecular subsets associated with differential clinical outcomes to angiogenesis blockade alone or with a checkpoint inhibitor. Unsupervised transcriptomic analysis reveals seven molecular subsets with distinct angiogenesis, immune, cell cycle, metabolism, and stromal programs. While sunitinib and atezolizumab+bevacizumab are effective in subsets with high angiogenesis, atezolizumab+bevacizumab improves clinical benefit in tumors with high T-effector and/or cell cycle transcription. Somatic mutations in PBRM1 and KDM5C associate with high angiogenesis and AMPK/Fatty acid oxidation gene expression, while CDKN2A/B and TP53 alterations associate with elevated cell cycle and anabolic metabolism. Sarcomatoid tumors exhibit lower prevalence of PBRM1 mutations and angiogenesis markers, frequent CDKN2A/B alterations, and increased PD-L1 expression. These findings can be applied to molecularly stratify patients, explain improved outcomes of sarcomatoid tumors to checkpoint blockade vs. anti-angiogenics alone, and develop personalized therapies in RCC and other indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
The Reactome pathway Knowledgebase
Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1351 · Cited by 5,605
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationxCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Self-citationThe Reactome Pathway Knowledgebase
Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P., Haw, R., Jassal, B., Korninger, F., May, B., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1132 · Cited by 2,855
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,503
Self-citationHypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
Metagenes and molecular pattern discovery using matrix factorization
Brunet, J.-P., Tamayo, P., Golub, T. R., & Mesirov, J. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308531101 · Cited by 2,183
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Heng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Self-citationFast and SNP-tolerant detection of complex variants and splicing in short reads
Wu, T. D., & Nacu, S. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq057 · Cited by 1,894
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Self-citationMutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
Rini, B. I., Campbell, S. C., & Escudier, B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,621
Self-citationCDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Self-citationMcDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Self-citationRini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C., Bracarda, S., Stadler, W. M., Donskov, F., Lee, J. L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30723-8 · Cited by 994
Self-citationŞenbabaoğlu, Y., Gejman, R. S., Winer, A. G., Liu, M., Van Allen, E. M., de Velasco, G., Miao, D., Ostrovnaya, I., Drill, E., Luna, A., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1092-z · Cited by 968
BAP1 loss defines a new class of renal cell carcinoma
Peña-Llopis, S., Vega-Rubín-de-Celis, S., Liao, A., Leng, N., Pavía-Jiménez, A., Wang, S., Yamasaki, T., Zhrebker, L., Sivanand, S., Spence, P., et al. (2012) · Nature Genetics · doi:10.1038/ng.2323 · Cited by 959
Self-citationTracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Chambers, T., Lopez, J. I., Nicol, D., O’Brien, T., Larkin, J., Horswell, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.057 · Cited by 829
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Ricketts, C. J., De Cubas, A. A., Fan, H., Smith, C. C., Lang, M., Reznik, E., Bowlby, R., Gibb, E. A., Akbani, R., Beroukhim, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.032 · Cited by 734
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
Clark, D. J., Dhanasekaran, S. M., Petralia, F., Pan, J., Song, X., Hu, Y., da Veiga Leprevost, F., Reva, B., Lih, T.-S. M., Chang, H.-Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.007 · Cited by 730
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal
Turajlic, S., Xu, H., Litchfield, K., Rowan, A., Horswell, S., Chambers, T., O’Brien, T., Lopez, J. I., Watkins, T. B. K., Nicol, D., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.043 · Cited by 655
Haas, B. J., Dobin, A., Li, B., Stransky, N., Pochet, N., & Regev, A. (2019) · Genome biology · doi:10.1186/s13059-019-1842-9 · Cited by 646
Shen, J., Ju, Z., Zhao, W., Wang, L., Peng, Y., Ge, Z., Nagel, Z. D., Zou, J., Wang, C., Kapoor, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0012-z · Cited by 562
Kapur, P., Peña-Llopis, S., Christie, A., Zhrebker, L., Pavía-Jiménez, A., Rathmell, W. K., Xie, X.-J., & Brugarolas, J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70584-3 · Cited by 471
Schaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.053 · Cited by 469
GMAP and GSNAP for Genomic Sequence Alignment: Enhancements to Speed, Accuracy, and Functionality
Wu, T. D., Reeder, J., Lawrence, M., Becker, G., & Brauer, M. J. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3578-9_15 · Cited by 431
Context-dependent roles of complement in cancer
Roumenina, L. T., Daugan, M. V., Petitprez, F., Sautès-Fridman, C., & Fridman, W. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0210-0 · Cited by 389
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
Chen, F., Zhang, Y., Şenbabaoğlu, Y., Ciriello, G., Yang, L., Reznik, E., Shuch, B., Micevic, G., De Velasco, G., Shinbrot, E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.024 · Cited by 359
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
Kaelin, W. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1865 · Cited by 336
Brannon, A. R., Reddy, A., Seiler, M., Arreola, A., Moore, D. T., Pruthi, R. S., Wallen, E. M., Nielsen, M. E., Liu, H., Nathanson, K. L., et al. (2010) · Genes & Cancer · doi:10.1177/1947601909359929 · Cited by 331
Beuselinck, B., Job, S., Becht, E., Karadimou, A., Verkarre, V., Couchy, G., Giraldo, N., Rioux-Leclercq, N., Molinié, V., Sibony, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1128 · Cited by 315
Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers
Kauffman, E. C., Ricketts, C. J., Rais-Bahrami, S., Yang, Y., Merino, M. J., Bottaro, D. P., Srinivasan, R., & Linehan, W. M. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.162 · Cited by 313
Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer
Linehan, W. M. (1995) · JAMA · doi:10.1001/jama.273.7.564 · Cited by 300
Dabestani, S., Thorstenson, A., Lindblad, P., Harmenberg, U., Ljungberg, B., & Lundstam, S. (2016) · World Journal of Urology · doi:10.1007/s00345-016-1773-y · Cited by 277
Yaari, G., Bolen, C. R., Thakar, J., & Kleinstein, S. H. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt660 · Cited by 261
Hakimi, A. A., Voss, M. H., Kuo, F., Sanchez, A., Liu, M., Nixon, B. G., Vuong, L., Ostrovnaya, I., Chen, Y.-B., Reuter, V., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0957 · Cited by 258
Self-citationGong, J., Li, Y., Liu, C.-J., Xiang, Y., Li, C., Ye, Y., Zhang, Z., Hawke, D. H., Park, P. K., Diao, L., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.070 · Cited by 249
Golshayan, A. R., George, S., Heng, D. Y., Elson, P., Wood, L. S., Mekhail, T. M., Garcia, J. A., Aydin, H., Zhou, M., Bukowski, R. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0000 · Cited by 229
Self-citationThe SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma
Nargund, A. M., Pham, C. G., Dong, Y., Wang, P. I., Osmangeyoglu, H. U., Xie, Y., Aras, O., Han, S., Oyama, T., Takeda, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.074 · Cited by 221
Identification of the von Hippel-Lindau (VHL) Gene: Its Role in Renal Cancer
Linehan, W. M. (1995) · JAMA · doi:10.1001/jama.1995.03520310062031 · Cited by 207
Wang, T., Lu, R., Kapur, P., Jaiswal, B. S., Hannan, R., Zhang, Z., Pedrosa, I., Luke, J. J., Zhang, H., Goldstein, L. D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1246 · Cited by 168
Gao, W., Li, W., Xiao, T., Liu, X. S., & Kaelin, W. G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619726114 · Cited by 167
The Function of Non-Coding RNAs in Lung Cancer Tumorigenesis
Braicu, C., Zimța, A., Haranguș, A., Iurca, I., Irimie, A., Coza, O. F., & Berindan‐Neagoe, I. (2019) · Cancers · doi:10.3390/cancers11050605 · Cited by 153
The lysine‐specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer
Rampias, T. N., Karagiannis, D., Avgeris, M., Polyzos, A., Kokkalis, A., Kanaki, Z., Kousidou, E., Tzetis, M., Kanavakis, E., STRAVODIMOS, K. G., et al. (2019) · EMBO Reports · doi:10.15252/embr.201846821 · Cited by 150
Rini, B. I., Plimack, E. R., Stus, V. P., Gafanov, R. A., Hawkins, R. E., Nosov, D., Pouliot, F., Soulières, D., Melichar, B., Vynnychenko, I. O., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4500 · Cited by 120
Self-citationJeong, E., Brady, O. A., Martina, J. A., Pirooznia, M., Tunc, I., & Puertollano, R. (2018) · eLife · doi:10.7554/elife.40856 · Cited by 114
McDermott, D. F., Choueiri, T. K., Motzer, R. J., Aren, O. R., George, S., Powles, T. B., Donskov, F. N., Harrison, M. R., Cid, J. R. R., Ishii, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4513 · Cited by 82
Self-citationSarcomatoid renal cell carcinoma: Biology and treatment advances
Mouallem, N. R. E., Smith, S. C., & Paul, A. K. R. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.12.012 · Cited by 71
Carlo, M. I., Manley, B. J., Patil, S., Woo, K. M., Coskey, D. T., Redzematovic, A., Arcila, M. E., Ladanyi, M., Lee, W., Chen, Y., et al. (2017) · Kidney Cancer · doi:10.3233/kca-160003 · Cited by 49
Self-citationChoueiri, T. K., Larkin, J., Pal, S. K., Motzer, R. J., Venugopal, B., Alekseev, B. Y., Miyake, H., Gravis, G., Bilen, M. A., Chudnovsky, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz249.009 · Cited by 35
Self-citationMaking adjuvant therapy decisions with uncertain data
Gyawali, B., & Prasad, V. K. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz039 · Cited by 19
A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC
Jonasch, E. W., Plimack, E. R., Bauer, T. M., Merchan, J. R., Papadopoulos, K. P., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S. I., Zojwalla, N. J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz249.010 · Cited by 14
Self-citation
Cited by
Renal Cell Carcinoma: A Review
Rose, T. L., & Kim, W. Y. (2024) · JAMA · doi:10.1001/jama.2024.12848 · Cited by 374
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
Au, L., Hatipoglu, E., Robert de Massy, M., Litchfield, K., Beattie, G., Rowan, A., Schnidrig, D., Thompson, R., Byrne, F., Horswell, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.001 · Cited by 260
Koh, M. Y., Sayegh, N., & Agarwal, N. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.008 · Cited by 28
Samnani, S., Sachedina, F., Gupta, M., Guo, E., & Navani, V. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.02 · Cited by 12
Metadata
- Authors
- Motzer, R. J., Banchereau, R., Hamidi, H., Powles, T., McDermott, D., Atkins, M. B., Escudier, B., Liu, L.-F., Leng, N., Abbas, A. R., Fan, J., Koeppen, H., Lin, J., Carroll, S., Hashimoto, K., Mariathasan, S., Green, M., Tayama, D., Hegde, P. S., Schiff, C., Huseni, M. A., & Rini, B.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 38
- Issue
- 6
- Pages
- 803-817.e4
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3096713247
- Cited by
- 569
- References
- 62
- FWCI
- 34.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.